Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib-Reference-Cited by-同舟云学术

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Published:2017-12 Issue:6 Volume:32 Page:761-776.e6
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Gong Xueqian,Litchfield Lacey M.,Webster Yue,Chio Li-Chun,Wong Swee Seong,Stewart Trent R.,Dowless Michele,Dempsey Jack,Zeng Yi,Torres Raquel,Boehnke Karsten,Mur Cecilia,Marugán Carlos,Baquero Carmen,Yu Chunping,Bray Steven M.,Wulur Isabella H.,Bi Chen,Chu Shaoyou,Qian Hui-Rong,Iversen Philip W.,Merzoug Farhana F.,Ye Xiang S.,Reinhard Christoph,De Dios Alfonso,Du Jian,Caldwell Charles W.,Lallena María José,Beckmann Richard P.,Buchanan Sean G.

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference62 articles.

1. Single-cell dynamics determines response to CDK4/6 inhibition in triple negative breast cancer;Asghar;Clin. Cancer Res.,2017

2. Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer;Barbash;Cancer Cell,2008

3. Dual inactivation of RB and p53 pathways in RAS-induced melanomas;Bardeesy;Mol. Cell. Biol.,2001

4. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity;Barretina;Nature,2012

5. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6;Baughn;Cancer Res.,2006

Cited by 177 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer;Current Oncology;2024-09-12

2. Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment;Drug Resistance Updates;2024-09

3. EWS-WT1 fusion isoforms establish oncogenic programs and therapeutic vulnerabilities in desmoplastic small round cell tumors;Nature Communications;2024-08-28

4. A Dual Bispecific Hydrolysis Peptide‐Drug Conjugate Responsive to Micro‐Acidic and Reduction Circumstance Promotes Antitumor Efficacy in Triple‐Negative Breast Cancer;ChemBioChem;2024-08-20

5. A review of trilaciclib, a first-in-class cyclin-dependent kinase 4/6 inhibitor, for the management of metastatic small-cell lung cancer;Medicinal Chemistry Research;2024-07-26